Alpheus Medical Opens Enrollment in New Clinical Trial for Butterfly Glioblastoma
The study will evaluate PoMA™ therapy, Alpheus' drug-led, tumor-selective treatment approach, in patients with butterfly glioblastoma, a particularly aggressive form of GBM involving both cerebral hemispheres. The trial design requires PoMA therapy prior to standard chemoradiation...
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Cancele cuando quiera · 99 CA$/mes


